Partnering opportunities

• Artificial intelligence/Machine learning (AI/ML)
• Synthesis and profiling automation
• Novel approaches to accelerate discovery and synthesis of new molecular entities
• Tissue targeting vectors for siRNA or Radioligand therapy (RLT)
• Preclinical small molecule leads for innovative therapies

Avi Spier

Contact

• Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery.
• Targeted delivery and selective tropism to key tissues/cell types
• Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates

Gianfranco de Pascale

Contact

• Novel T-cell-based therapy approaches for haematology & solid tumors
• Approaches to reduce AAV immunogenicity
• NextGen gene editing (non-viral)
• Novel capsids with focus on CNS and Ophthalmology targeting

Markus Werner (Oncology)

Contact

Elizabeth Leshen (Rare diseases and neuroscience)

Contact

• Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types
• Innovative siRNA chemistry platforms
• In vivo/In vitro platforms to identify and validate siRNA targets

Gianfranco de Pascale

Contact

• Discovery of new RLT binders (“vectors”)
• Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery
• Explore various combination approaches which are synergistic with RLTs

Marcel Reichen

Contact

Novartis is open to discussing the divestment of certain commercial products in different regions, as well as granting licenses to development-stage compounds that have been de-prioritized due to strategic reasons.

Out licensing

Sven Werner

Contact

Divestments

Jean Marc Séquier

Contact

We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:

• Enable deeper understanding of disease
• Power small and large molecule design
• Increase predictive safety
• Improve trial design

Cynthia Hong

Contact

Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.

Guy Greiveldinger

Contact

Frank Dieterle

Contact

Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.

Charles Bailey

Contact